{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T08:52:23Z","timestamp":1792399943752,"version":"4.4.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,6,25]],"date-time":"2018-06-25T00:00:00Z","timestamp":1529884800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.lpm.2018.06.004","type":"journal-article","created":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T01:57:53Z","timestamp":1537840673000},"page":"854-866","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["D\u00e9veloppement des biosimilaires de l\u2019insuline\u00a0: exemple de l\u2019insuline glargine\u00a0LY2963016"],"prefix":"10.1016","volume":"47","author":[{"given":"Jean-Jacques","family":"Altman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7160-4301","authenticated-orcid":false,"given":"Nicolas","family":"Chevalier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Delemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Travert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imane","family":"Benabbad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2018.06.004_bib0185","series-title":"Guideline for diabetes in childhood and adolescence","author":"Global IDF\/ISPAD","year":"2011"},{"key":"10.1016\/j.lpm.2018.06.004_bib0190","series-title":"Type 1\u00a0Diabetes Treatment Guideline","year":"2017"},{"issue":"7","key":"10.1016\/j.lpm.2018.06.004_bib0195","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.2337\/dc14-1140","article-title":"Type 1\u00a0Diabetes Sourcebook authors. Type 1\u00a0diabetes through the life span: a position statement of the American Diabetes Association","volume":"37","author":"Chiang","year":"2014","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.lpm.2018.06.004_bib0200","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","article-title":"Management of Hyperglycemia in Type 2\u00a0Diabetes, 2015: a patient-centered approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"38","author":"Inzucchi","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.lpm.2018.06.004_bib0205","series-title":"Global guideline for type 2\u00a0diabetes","year":"2012"},{"key":"10.1016\/j.lpm.2018.06.004_bib0210","series-title":"Les biosimilaires en 15 questions. Rapport C Lepen","author":"ANSM","year":"2014"},{"issue":"1","key":"10.1016\/j.lpm.2018.06.004_bib0215","first-page":"17","article-title":"Produits biologiques et biosimilaires\u00a0: science et implications. Biopharmaceuticals and biosimilars: science and implications","volume":"32","author":"Declerck","year":"2013","journal-title":"J Pharm Clin"},{"issue":"1","key":"10.1016\/j.lpm.2018.06.004_bib0220","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2515\/therapie\/2014233","article-title":"Les participants \u00e0 la table ronde No3\u00a0de Giens XXX. Biosimilaires\u00a0: de la technique au m\u00e9dico\u00e9conomique","volume":"70","author":"Girault","year":"2015","journal-title":"Therapie"},{"key":"10.1016\/j.lpm.2018.06.004_bib0225","series-title":"\u00c9tat des lieux sur les m\u00e9dicaments biosimilaires","author":"ANSM","year":"2016"},{"key":"10.1016\/j.lpm.2018.06.004_bib0230","series-title":"Guideline on similar biological medicinal products","author":"EMA","year":"2014"},{"key":"10.1016\/j.lpm.2018.06.004_bib0235","series-title":"Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues","author":"EMA","year":"2014"},{"key":"10.1016\/j.lpm.2018.06.004_bib0240","series-title":"Procedural advice for users of the centralised procedure for similar biological medicinal products applications","author":"EMA","year":"2015"},{"issue":"5","key":"10.1016\/j.lpm.2018.06.004_bib0245","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/dom.12410","article-title":"Biosimilar insulins: a European perspective","volume":"17","author":"DeVries","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"10.1016\/j.lpm.2018.06.004_bib0250","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1089\/dia.2012.0105","article-title":"The emergence of biosimilar insulin preparations\u00a0\u2013\u00a0a cause for concern?","volume":"14","author":"Owens","year":"2012","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.lpm.2018.06.004_bib0255","unstructured":"Directive 2004\/27\/EC Art. 10(2) b, 31 mars 2004. [Disponible sur\u00a0: http:\/\/ec.europa.eu\/health\/files\/eudralex\/vol-1\/dir_2004_27\/dir_2004_27_fr.pdf (Consult\u00e9 le 11 janvier 2017)]"},{"key":"10.1016\/j.lpm.2018.06.004_bib0260","unstructured":"Biom\u00e9dicaments en France. \u00c9tat des lieux 2014\u2013Leem septembre 2014. [Disponible sur\u00a0: https:\/\/www.leem.org\/sites\/default\/files\/Biom%C3%A9dicaments-etat-des-lieux-2014.pdf (Consult\u00e9 le 11 janvier 2017)]."},{"key":"10.1016\/j.lpm.2018.06.004_bib0265","series-title":"Guideline on the investigation of bioequivalence","author":"EMA","year":"2010"},{"key":"10.1016\/j.lpm.2018.06.004_bib0270","series-title":"Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1)","author":"EMA","year":"2014"},{"key":"10.1016\/j.lpm.2018.06.004_bib0275","first-page":"345","article-title":"Comment nous pr\u00e9parer \u00e0 l\u2019arriv\u00e9e des biosimilaires de l\u2019insuline\u00a0?","volume":"9","author":"Vialettes","year":"2015","journal-title":"Medecine Mal Metab"},{"key":"10.1016\/j.lpm.2018.06.004_bib0280","series-title":"Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues","author":"EMA","year":"2015"},{"key":"10.1016\/j.lpm.2018.06.004_bib0285","series-title":"Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins","author":"EMA","year":"2015"},{"key":"10.1016\/j.lpm.2018.06.004_bib0290","unstructured":"EMA\/CHMP\/340840\/2014. [Disponible sur\u00a0: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002835\/WC500175383.pdf (Consult\u00e9 le 11 janvier 2017)]"},{"issue":"12","key":"10.1016\/j.lpm.2018.06.004_bib0295","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.2337\/dc14-2623","article-title":"Comparison of the pharmacokinetics and pharmacodynamics of LY2963016\u00a0insulin glargine and European Union- and U.S.-approved versions of Lantus insulin glargine in healthy subjects: three randomized euglycemic clamp studies","volume":"38","author":"Linnebjerg","year":"2015","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.lpm.2018.06.004_bib0300","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/dom.12496","article-title":"Efficacy and safety of LY2963016\u00a0insulin glargine compared with insulin glargine (Lantus\u00ae) in patients with type 1\u00a0diabetes in a randomized controlled trial: the ELEMENT 1\u00a0study","volume":"17","author":"Blevins","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"10.1016\/j.lpm.2018.06.004_bib0305","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/dom.12482","article-title":"Similar efficacy and safety of LY2963016\u00a0insulin glargine and insulin glargine (Lantus\u00ae) in patients with type 2\u00a0diabetes who were insulin-na\u00efve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2\u00a0study)","volume":"17","author":"Rosenstock","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.lpm.2018.06.004_bib0310","series-title":"Guideline on the choice of the non-inferiority margin","author":"EMA","year":"2005"},{"issue":"2","key":"10.1016\/j.lpm.2018.06.004_bib0315","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/dom.12584","article-title":"Evaluation of immunogenicity of LY2963016\u00a0insulin glargine compared with Lantus\u00ae insulin glargine in patients with type 1\u00a0or type 2\u00a0diabetes mellitus","volume":"18","author":"Ilag","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.lpm.2018.06.004_bib0320","series-title":"Consensus information paper 2013. What you need to know about biosimilar medicinal products","author":"European Commission, Enterprise and Industry Directorate-General","year":"2013"},{"key":"10.1016\/j.lpm.2018.06.004_bib0325","unstructured":"Instruction No DGOS\/PF2\/DSS\/1C\/DGS\/PP2\/CNAMTS\/2017\/244 du 3 ao\u00fbt 2017 relative aux m\u00e9dicaments biologiques, \u00e0 leurs similaires ou \u00ab\u00a0biosimilaires\u00a0\u00bb, et \u00e0 l\u2019interchangeabilit\u00e9 en cours des traitements, 28 juillet 2017. [Disponible sur\u00a0: http:\/\/circulaire.legifrance.gouv.fr\/pdf\/2017\/10\/cir_42638.pdf (Consult\u00e9 le 11 janvier 2017)]."},{"key":"10.1016\/j.lpm.2018.06.004_bib0330","series-title":"LFSS article 47","year":"2018"},{"key":"10.1016\/j.lpm.2018.06.004_bib0335","unstructured":"D\u00e9cret no\u00a02016\u2013960 du 12 juillet 2016 relatif \u00e0 l\u2019inscription des m\u00e9dicaments biologiques similaires sur la liste de r\u00e9f\u00e9rence des groupes biologiques similaires. [Disponible sur\u00a0: https:\/\/www.legifrance.gouv.fr\/affichTexte.do?cidTexte=JORFTEXT000032891743&dateTexte=20160718 (Consult\u00e9 le 11 janvier 2017)]"},{"key":"10.1016\/j.lpm.2018.06.004_bib0340","series-title":"Les m\u00e9dicaments biosimilaires. Compte rendu de l\u2019audition publique du 29\u00a0janvier 2015\u00a0et de la pr\u00e9sentation des conclusions du 6\u00a0mai","author":"Rapport du s\u00e9nat mai 2015","year":"2015"},{"key":"10.1016\/j.lpm.2018.06.004_bib0345","series-title":"Assessing biosimilar uptake and competition in European markets \u2013\u00a0IMS","year":"2014"},{"key":"10.1016\/j.lpm.2018.06.004_bib0350","unstructured":"Perspectives du march\u00e9 mondial des produits biosimilaires - Focus sp\u00e9cifique sur le march\u00e9 fran\u00e7ais (Pr\u00e9visions \u00e0 2017) Smart Pharma Consulting, f\u00e9vrier 2015 [Disponible sur\u00a0: http:\/\/www.smart-pharma.com\/uploads\/files\/Extraits-du-Rapport-Biosimilaires-2015-Fr.pdf (Consult\u00e9 le 11 janvier 2017)]."},{"key":"10.1016\/j.lpm.2018.06.004_bib0355","unstructured":"R\u00e9sum\u00e9 des caract\u00e9ristiques du produit \u2013\u00a0Insuline glargine Lantus\u00ae [http:\/\/ec.europa.eu\/health\/documents\/community-register\/2017\/20171003139003\/anx_139003_fr.pdf, consult\u00e9 le 11 janvier 2017]."},{"key":"10.1016\/j.lpm.2018.06.004_bib0180","series-title":"Europe position on biosimilars in the treatment of people with diabetes","author":"IDF","year":"2017"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498218302690?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498218302690?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:04:02Z","timestamp":1760105042000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498218302690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0755498218302690"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2018.06.004","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"D\u00e9veloppement des biosimilaires de l\u2019insuline\u00a0: exemple de l\u2019insuline glargine\u00a0LY2963016","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2018.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}